NCT05149014View on ClinicalTrials.gov

Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer

CompletedOBSERVATIONAL
Enrollment

306

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions
HER2-positive Breast Cancer
Trial Locations (1)

Unknown

Clinique des Flandres, Coudekerque-Branche

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo France

INDUSTRY

NCT05149014 - Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer | Biotech Hunter | Biotech Hunter